Mass drug administration of DHA-PQP to accelerate towards malaria elimination in Magude district, Southern Mozambique

• Drug & regimen: 2 rounds for 2 consecutive years of dihydroartemisinin-piperaquine for 3 days, with the first dose administered directly house-to-house
• Concomitant interventions: IRS, LLINs, community engagement and the standard case management offered by the MoH
• Target size & population: The study population has 50,000 inhabitants
• Inclusion criteria: Older than 6 months of age or more than 5kg, women on the second or third trimester who are not on IPTp
• Exclusion criteria: Younger than 6 months of age or less than 5 kg, women in the first trimester of pregnancy, severely ill individuals and contraindications
• Outcome measures (primary and secondary) and tool used:
  • Prevalence of malaria infection (by RDT and/or PCR) in a subgroup of the study population on month six
  • Incidence of malaria as detected through passive case detection (weekly cases reported through a Rapid Reporting System) 
  • Identification of hotspots of maintained transmission in the study area
  • Coverage achieved of MDA 1-4 rounds
• Time of follow-up: 12 months
• Clinicaltrials.gov ID: NCT02914145

Type: Interventional
Allocation: Non-Randomized
Intervention model: Single group
Masking: None (open label)
Primary Purpose: Treatment

Mass Drug Administrations of DHA-PQP to Accelerate Towards Malaria Elimination

Drug-based Strategies

Jan 2015 — Dec 2017

Mozambique

Mozambican Alliance Towards Elimination of Malaria (MALTEM)

Mass Drug Administration (MDA)
Tracking progress against the PMI Insights Research Priorities